PITTSBURGH, May 22, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that the Company will participate in two upcoming healthcare conferences in June 2025.The Company will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 5, 2025, at 8:10 a.m. ET.In addition, the Company will take part in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference 2025 on June 9, 2025, at 10:40 a.m. ET.Investors and the genera ...

NEW YORK, May 22, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Viatris Inc. (NASDAQ: VTRS).Shareholders who purchased shares of VTRS during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/viatris-inc-loss-submission-form-2/?id=149527&from=4CLASS PERIOD: August 8, 2024 to February ...

Core Viewpoint - A securities class action lawsuit has been filed against Viatris Inc. for allegedly misleading investors during the Class Period from August 8, 2024, to February 26, 2025 [1][3]. Company Overview - Viatris is a healthcare company based in Canonsburg, PA, that provides medicines to one billion patients globally [2]. Legal Context - The lawsuit claims that Viatris misled investors by downplaying the consequences of a failed inspection at its Indore, India facility and a Warning Letter from the U.S. Food and Drug Administration [3]. - Investors who purchased Viatris securities during the Class Period have until June 3, 2025, to seek appointment as lead plaintiff [2]. Law Firm Background - Berger Montague, the law firm handling the case, has been involved in securities class action litigation since 1970 and has represented both individual and institutional investors [5].

The Stock Declines as the Truth is Revealed On February 27, 2025, the Company released its Q4 2024 results and provided 2025 guidance. The Company revealed that the "negative impact" of the Indore facility's failed inspection would lower 2025 revenue by "approximately $500 million" and 2025 earnings from operations by "approximately $385 million." The Company further disclosed that the failed inspection at its Indore facility prevented it from identifying alternative supply options for Lenalidomide and from ...

NEW YORK, May 19, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Viatris Inc. ("Viatris" or the "Company") (NASDAQ: VTRS) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Viatris investors who were adversely affected by alleged securities fraud between August 8, 2024 and February 26, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/viatris-inc-lawsuit-submission- ...

NEW YORK, May 19, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Viatris Inc. (NASDAQ: VTRS).Shareholders who purchased shares of VTRS during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/viatris-inc-loss-submission-form-2/?id=148823&from=4CLASS PERIOD: August 8, 2024 to February ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Viatris Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline on June 3, 2025, for a class action lawsuit [1][2]. Group 1: Class Action Details - Investors who bought Viatris securities between August 8, 2024, and February 26, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by June 3, 2025 [2]. Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time and being ranked No. 1 for the number of settlements in 2017 [3]. - The firm has recovered hundreds of millions of dollars for investors, securing over $438 million in 2019 alone [3]. Group 3: Case Background - The lawsuit alleges that during the Class Period, Viatris provided misleading information regarding the failed inspection of its Indore, India facility, including the issuance of an FDA warning letter that impacted the shipment of eleven products [4]. - Defendants allegedly downplayed the significance of the warning letter, referring to it as a "minor headwind," while failing to disclose critical details about the inspection, remediation efforts, and the financial implications for Viatris [5].

NEW YORK, May 17, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Viatris Inc. (NASDAQ: VTRS) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Viatris, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/viatris-inc. Investors have until June 3, 2025, to ask the Court to be appointed to lead the case. ...

Core Viewpoint - A class action securities lawsuit has been filed against Viatris Inc. due to alleged securities fraud impacting investors between August 8, 2024, and February 26, 2025 [1] Group 1: Lawsuit Details - The lawsuit claims that Viatris misrepresented the implications of a warning letter from the FDA regarding its Indore, India facility, downplaying its significance as a "minor headwind" [2] - Following the announcement of disappointing financial results for Q4 and fiscal year 2024 on February 27, 2025, Viatris' stock price dropped from $11.24 to $9.53, a decline of approximately 15.21% in one day [2] Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until June 3, 2025, to request appointment as lead plaintiff, although participation does not require this role [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees [3] Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions for shareholders and is recognized as one of the top securities litigation firms in the U.S. [4]

NEW YORK, May 15, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Viatris Inc. (NASDAQ: VTRS). Shareholders who purchased shares of VTRS during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/viatris-inc-loss-submission-form-2/?id=148457&from=3 CLASS PERIOD: August 8, 2024 to F ...